Publikationen in Zusammenarbeit mit Forschern von Università di Perugia (9)

2018

  1. Lead optimization-hit expansion of new asymmetrical pyridinium/quinolinium compounds as choline kinase α1 inhibitors

    Future Medicinal Chemistry, Vol. 10, Núm. 15, pp. 1769-1786

2015

  1. Pharmacophore-Based Virtual Screening to Discover New Active Compounds for Human Choline Kinase α1

    Molecular Informatics, Vol. 34, Núm. 6-7, pp. 458-466

2014

  1. Choline kinase active site provides features for designing versatile inhibitors

    Current Topics in Medicinal Chemistry, Vol. 14, Núm. 23, pp. 2684-2693

2006

  1. Back door modulation of the farnesoid X receptor: Design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives

    Journal of Medicinal Chemistry, Vol. 49, Núm. 14, pp. 4208-4215

2005

  1. Molecular dynamics simulation of the ligand binding domain of farnesoid X receptor. Insights into helix-12 stability and coactivator peptide stabilization in response to agonist binding

    Journal of Medicinal Chemistry, Vol. 48, Núm. 9, pp. 3251-3259

2004

  1. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure - Activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid

    Journal of Medicinal Chemistry, Vol. 47, Núm. 18, pp. 4559-4569

2003

  1. Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR)

    Bioorganic and Medicinal Chemistry Letters, Vol. 13, Núm. 11, pp. 1865-1868

2001

  1. Conformational analysis of carboxyphenylglycine (CPG) derivatives: Insight into bioactive and bioselective conformations of group-I mGluRs antagonists

    Farmaco, Vol. 56, Núm. 11, pp. 891-898

  2. QSAR and molecular modeling studies of baclofen analogues as GABAB agonists. Insights into the role of the aromatic moiety in GABAB binding and activation

    Journal of Medicinal Chemistry, Vol. 44, Núm. 11, pp. 1827-1832